Arrowhead's ARO-MAPT Shows 73% Tau Reduction in Early Trial Data

  • ARO-MAPT achieved mean tau reduction of 73% in healthy volunteers at Day 105, with maximum reduction of 85%.
  • Subcutaneous administration demonstrated durability with potential for quarterly dosing.
  • Phase 1/2a study includes both healthy volunteers and early Alzheimer’s patients.
  • No serious adverse events reported; most were mild injection-site reactions.
  • Arrowhead plans to initiate trials for frontotemporal dementia and Progressive Supranuclear Palsy.

Arrowhead’s success in delivering siRNA across the blood-brain barrier represents a major milestone in neurodegenerative disease treatment. The durable tau reduction in healthy volunteers validates the company’s TRiM platform, positioning it as a leader in RNAi therapeutics for CNS disorders. This breakthrough could accelerate development of treatments for Alzheimer’s and other tauopathies, addressing a significant unmet medical need.

Clinical Validation
Whether Arrowhead can replicate these results in Alzheimer’s patients and other tauopathies.
Regulatory Pathway
The pace at which Arrowhead advances discussions for additional indications.
Competitive Positioning
How this breakthrough solidifies Arrowhead’s leadership in CNS-targeted RNAi therapies.